Polymorphic and salt forms of (1S,3S)-N1-(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine
Polymorphic and salt forms of (1S,3S)-N1-(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine enhance solubility and pharmacokinetics, addressing the need for effective CDK9 inhibitors to treat cancer, particularly glioblastoma.
Patent Information
- Application Number
- JP2024531065
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-24
- Filing Date
- 2022-11-22
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for cancer, particularly glioblastoma, are resistant to many existing therapies, and there is a need for more effective inhibitors of cyclin-dependent kinase 9 (CDK9) to target key oncogenic proteins and transcription factors.
Development of polymorphic and salt forms of (1S,3S)-N1-(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine, characterized by X-ray diffraction, differential scanning calorimetry, and thermogravimetric analysis, to enhance solubility and pharmacokinetic properties for targeted cancer therapy.
The polymorphic and salt forms of Compound A provide enhanced solubility and pharmacokinetic properties, offering a more effective treatment for cancer by inhibiting CDK9 and affecting key survival pathways.
Smart Images

Figure 2024543136000001_ABST
Abstract
Description
[Technical field]
[0001] Introduction (1S,3S)-N 1 -(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine is a pharma- ceutical active compound being investigated for a variety of uses, e.g., for the treatment of cancer. As used herein, the term "Compound A" refers to (1S,3S)-N 1 -(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine is used to refer to both the free base and salt forms. The free base of Compound A has the CAS number 2416873-83-9 and formula (I): [ka] It has the structure: [Background technology]
[0002] For example, compound A has been reported to be a selective inhibitor of cyclin-dependent kinase 9 (CDK9) that showed antitumor activity in in vitro and in vivo cancer models (Richters et al, Cell Chemical Biology, 2021, 28, 2, 134, doi: 10.1016 / j.chembiol.2020.10.001). Indeed, it has been reported that inhibiting CDK9, for example with compound A, may affect multiple survival pathways in cancer and may be a therapeutic approach against glioblastoma, a subtype of cancer that is resistant to many existing treatments (Ranjan et al, Cancers, 2021, 13, 12, 3039, doi:10.3390 / cancers13123039).
[0003] Cyclin-dependent kinase (CDK) family proteins are key regulators of cell cycle and gene transcription. The cell cycle is a regulatory cellular mechanism for timing cell growth and division. It is a multifaceted process that directs cell proliferation through a series of checkpoints that correct DNA damage, genetic abnormalities, and other errors (Nonhuman Primates in Biomedical Research 20, Second Edition, 2012). Each stage is controlled by a combination of cyclins and CDKs, where CDKs phosphorylate specific sets of cyclins to induce transition to the next stage of the cell cycle (Merri Lynn Casem, "Case Studies in Cell Biology", Chapter 13 - Cell Cycle, 2016, doi:10.1016 / B978-0-12-801394-6.00013-0). The accumulation of cyclin proteins through regulation of cyclin mRNA transcription functions as a "biological switch" that turns CDKs on and off, moving the cell from one stage to the next (Id.).
[0004] CDK1, 2, 3, 4 and 6 regulate the timing of the cell division cycle, while CDK7 and CDK9 regulate transcriptional activity by regulating RNA polymerase II via phosphorylation of the carboxy-terminal domain (Lucking et al, ChemMedChem, 2017, 12, 1776, doi: 10.1002 / cmdc.201700447). CDK9 controls the transcriptional activity of key oncogenic proteins such as AR, MYC, MCL-1 and BCL-2, and stimulates proinflammatory transcription factors such as NFkB and STAT3 (Gregory et al, Leukemia, 2015, 29, 1437, doi:10.1038 / leu.2015.10; Krystof et al, Current Pharmaceutical Design, 18, 20, 2883, doi:10.2174 / 138161212800672750). CDK9 heterodimerizes with one of four cyclin partners (cyclin T1, cyclin K, cyclin T2a, or cyclin T2b) called positive transcription elongation factor (PTEFb). RNA polymerase II pauses mRNA transcription after 20-40 nucleotides along the DNA template through the interaction of negative elongation factors, which serve as the primary regulatory control mechanism for transcription of rapidly induced genes. PTEFb overcomes the pausing of RNA polymerase II by phosphorylation of the carboxy-terminal domain of RNA polymerase II and the inactivation of negative elongation factors. Compounds targeting CDK9 and PTEFb are currently under clinical investigation. The enzymatic activity of CDK9 is important for stimulating transcription elongation of most protein-coding genes (Krystof et al, Current Pharmaceutical Design, 18, 20, 2883, doi:10.2174 / 138161212800672750). [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Richters et al, Cell Chemical Biology, 2021, 28, 2, 134, doi: 10.1016 / j.chembiol.2020.10.001 [Non-Patent Document 2] Ranjan et al, Cancers, 2021, 13, 12, 3039, doi:10.3390 / cancers13123039 [Non-Patent Document 3] Nonhuman Primates in Biomedical Research 20, Second Edition, 2012 [Non-Patent Document 4] Merri Lynn Casem, "Case Studies in Cell Biology", Chapter 13 - Cell Cycle, 2016, doi:10.1016 / B978-0-12-801394-6.00013-0 [Non-Patent Document 5] Lucking et al, ChemMedChem, 2017, 12, 1776, doi: 10.1002 / cmdc.201700447 [Non-Patent Document 6] Gregory et al, Leukemia, 2015, 29, 1437, doi:10.1038 / leu.2015.10 [Non-Patent Document 7] Krystof et al, Current Pharmaceutical Design, 18, 20, 2883, doi:10.2174 / 138161212800672750 [Summary of the Invention] [Means for Solving the Problems]
[0006] Summary (1S,3S)-N 1Polymorphic and salt forms of Compound A, also known as -(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine, are provided. Polymorphic forms of the free base of Compound A are provided, along with polymorphic forms of salts of Compound A, including tosylate, oxalate, fumarate, camsylate, citrate, hydrochloride, and naphthalene-1,5-disulfonate. Such forms have been characterized by X-ray diffraction (XRD), differential scanning calorimetry (DSC), and thermogravimetric analysis coupled to mass spectrometry (TGA-MS). Such polymorphic and salt forms can have desirable solubility, dissolution, and pharmacokinetic properties.
[0007] In some embodiments, polymorphic forms of the free base of Compound A are provided by the present disclosure. In one aspect, polymorphic forms I, II, and III of the free base of Compound A are provided. In some cases, form III is amorphous. In some cases, such forms are characterized by X-ray diffraction (XRD) patterns, differential scanning calorimetry (DSC) thermograms, and thermogravimetry-mass spectrometry (TGA-MS) spectra substantially as shown in Figures 1-6, 7A-7C, 8A-8C, and 9A-9C.
[0008] In some embodiments, polymorphic forms of a tosylate salt of Compound A are provided. In one aspect, forms I, II, III, and IV of a tosylate salt of Compound A are provided. In some cases, such forms are characterized by XRD, DSC, and TGA-MS spectra substantially as depicted in Figures 10-17.
[0009] In some embodiments, polymorphic forms of the oxalate salt of Compound A are provided. In one aspect, forms I, II, and III of the oxalate salt of Compound A are provided. In some cases, such forms are characterized by XRD, DSC, and TGA-MS spectra substantially as shown in Figures 19-27.
[0010] In some embodiments, polymorphic forms of the fumarate salt of Compound A are provided. In one aspect, forms I, II, III, IV, and V of the oxalate salt of Compound A are provided. In some cases, such forms are characterized by XRD, DSC, and TGA-MS spectra substantially as depicted in Figures 29-35.
[0011] In some embodiments, polymorphic forms of the camsylate salt of Compound A are provided. In one aspect, forms I, II, and III of the camsylate salt of Compound A are provided. In some cases, such forms are characterized by XRD, DSC, and TGA-MS spectra substantially as depicted in Figures 37-42.
[0012] In some embodiments, polymorphic forms of a citrate salt of Compound A are provided. In one aspect, Form I of a citrate salt of Compound A is provided. In some instances, such forms are characterized by XRD, DSC, and TGA-MS spectra substantially as depicted in Figures 44-46.
[0013] In some embodiments, polymorphic forms of the hydrochloride salt of Compound A are provided. In one aspect, forms I, II, and III of the oxalate salt of Compound A are provided. In some cases, such forms are characterized by XRD, DSC, and TGA-MS spectra substantially as depicted in Figures 47-53.
[0014] In some embodiments, polymorphic forms of naphthalene-1,5-disulfonate salt of Compound A are provided. In one aspect, Form I of naphthalene-1,5-disulfonate salt of Compound A is provided. In some cases, such forms are characterized by XRD, DSC, and TGA-MS spectra substantially as shown in FIG.
[0015] Methods for synthesizing polymorphs of formula (I) described herein are provided. In some cases, the methods are methods for synthesizing polymorphs of tosylate, oxalate, fumarate, camsylate, citrate, hydrochloride, or naphthalene-1,5-disulfonate salts of formula (I). Such methods can include (i) contacting a free base of compound A with a solvent and a compound comprising a tosylate moiety, an oxalate moiety, a fumarate moiety, a camsylate moiety, a citrate moiety, a chloride moiety, or a naphthalene-1,5-disulfonic acid moiety, thereby producing a composition comprising the solvent and a salt of formula (I), and (ii) evaporating the solvent to produce a solid product.
[0016] Pharmaceutical compositions are provided that include a polymorphic form of Formula (I) described herein and a pharma- ceutically acceptable carrier.
[0017] Kits are provided that include (i) a polymorphic form of Formula (I) as described herein or a pharmaceutical composition comprising such a polymorphic form, and (ii) instructions for using the polymorphic form or pharmaceutical composition.
[0018] Provided is a method of treating a condition in a subject, comprising administering to the subject a polymorphic form of formula (I) as described herein or a pharmaceutical composition comprising such a polymorphic form. In some cases, the subject is a human. In some cases, the condition is cancer or an autoimmune disease. [Brief description of the drawings]
[0019] [Figure 1-1] FIG. 1 shows the X-ray diffraction (XRD) pattern of the free base, Form I. [Figure 1-2] FIG. 1 shows the X-ray diffraction (XRD) pattern of the free base, Form I.
[0020] [Diagram 2] FIG. 2 shows a differential scanning calorimetry (DSC) thermogram of the free base, Form I.
[0021] [Diagram 3] FIG. 3 shows the thermogravimetric-mass spectrometry (TGA-MS) characterization of the free base, Form I.
[0022] [Figure 4-1] FIG. 4 shows the XRD pattern of the free base, Form II. [Figure 4-2] FIG. 4 shows the XRD pattern of the free base, Form II.
[0023] [Diagram 5] FIG. 5 shows the DSC thermogram of the free base, Form II.
[0024] [Figure 6-1] FIG. 6 shows the TGA-MS characterization of the free base, Form II. [Figure 6-2] FIG. 6 shows the TGA-MS characterization of the free base, Form II.
[0025] [Figure 7A] FIG. 7A shows the XRD pattern of the free base, Form III, Run 1.
[0026] [Figure 7B] FIG. 7B shows the DSC thermogram of the free base, Form III, Run 1.
[0027] [Figure 7C-1] FIG. 7C shows the TGA-MS characterization of the free base, Form III, Exp. 1. [Figure 7C-2] FIG. 7C shows the TGA-MS characterization of the free base, Form III, Exp. 1.
[0028] [Figure 7D] FIG. 7D shows the XRD patterns of the free base immediately (bottom) and after 45 minutes (top) of slow evaporation of the ethanol solution.
[0029] [Figure 8A]FIG. 8A shows the XRD pattern of the free base, Form III, Run 2.
[0030] [Figure 8B] FIG. 8B shows the DSC thermogram of the free base, Form III, Run 2.
[0031] [Figure 8C] FIG. 8C shows the TGA-MS characterization of the free base, Form III, Run 3.
[0032] [Figure 9A] FIG. 9A shows the XRD pattern of the free base, Form III, Run 3.
[0033] [Figure 9B] FIG. 9B shows the DSC thermogram of the free base, Form III, Run 3.
[0034] [Figure 9C] FIG. 9C shows the TGA-MS characterization of the free base, Form III, Run 3.
[0035] [Figure 10-1] FIG. 10 shows the XRD pattern of the tosylate salt, Form I. [Figure 10-2] FIG. 10 shows the XRD pattern of the tosylate salt, Form I.
[0036] [Figure 11] FIG. 11 shows the DSC thermogram of the tosylate salt, Form I.
[0037] [Figure 12] FIG. 12 shows the TGA-MS characterization of the tosylate salt, Form I.
[0038] [Figure 13-1] FIG. 13 shows the XRD pattern of the tosylate salt, Form II. [Figure 13-2] FIG. 13 shows the XRD pattern of the tosylate salt, Form II.
[0039] [Figure 14-1] FIG. 14 shows the XRD pattern of the tosylate salt, Form III. [Figure 14-2] FIG. 14 shows the XRD pattern of the tosylate salt, Form III.
[0040] [Figure 15] FIG. 15 shows the DSC thermogram of the tosylate salt, Form III.
[0041] [Figure 16] FIG. 16 shows the TGA-MS characterization of the tosylate salt, Form III.
[0042] [Figure 17-1] FIG. 17 shows the XRD pattern of the tosylate salt, Form IV. [Figure 17-2] FIG. 17 shows the XRD pattern of the tosylate salt, Form IV.
[0043] [Figure 18] FIG. 18 shows the XRD pattern overlay of the tosylate salt, Forms I through IV.
[0044] [Figure 19] FIG. 19 shows the XRD pattern of the Oxalate Salt, Form I.
[0045] [Figure 20] FIG. 20 shows the DSC thermogram of the Oxalate Salt, Form I.
[0046] [Figure 21] FIG. 21 shows the TGA-MS characterization of the Oxalate Salt, Form I.
[0047] [Figure 22] FIG. 22 shows the XRD pattern of the oxalate salt, Form II.
[0048] [Diagram 23] FIG. 23 shows the DSC thermogram of the oxalate salt, Form II.
[0049] [Figure 24] FIG. 24 shows the TGA-MS characterization of the oxalate salt, Form II.
[0050] [Figure 25-1] FIG. 25 shows the XRD pattern of the oxalate salt, Form III. [Figure 25-2] FIG. 25 shows the XRD pattern of the oxalate salt, Form III.
[0051] [Figure 26] FIG. 26 shows the DSC thermogram of the oxalate salt, Form III.
[0052] [Figure 27-1] FIG. 27 shows the TGA-MS characterization of the oxalate salt, Form III. [Figure 27-2] FIG. 27 shows the TGA-MS characterization of the oxalate salt, Form III.
[0053] [Figure 28] FIG. 28 shows the overlaid XRD patterns of the oxalate salt.
[0054] [Figure 29] FIG. 29 shows the XRD pattern of the fumarate salt, Form I.
[0055] [Figure 30-1] FIG. 30 shows the XRD pattern of the fumarate salt, Form II. [Figure 30-2] FIG. 30 shows the XRD pattern of the fumarate salt, Form II.
[0056] [Figure 31-1] FIG. 31 shows the XRD pattern of the fumarate salt, Form III. [Figure 31-2]FIG. 31 shows the XRD pattern of the fumarate salt, Form III.
[0057] [Diagram 32] FIG. 32 shows the DSC thermogram of the fumarate salt, Form III.
[0058] [Diagram 33] FIG. 33 shows the TGA-MS characterization of the fumarate salt, Form III.
[0059] [Diagram 34] FIG. 34 shows the XRD pattern of the fumarate salt, Form IV.
[0060] [Diagram 35] FIG. 35 shows the XRD pattern of the fumarate salt, Form V.
[0061] [Diagram 36] FIG. 36 shows the overlay of the XRD patterns of the fumarate salt.
[0062] [Figure 37-1] FIG. 37 shows the XRD pattern of the camsylate salt, Form I. [Figure 37-2] FIG. 37 shows the XRD pattern of the camsylate salt, Form I.
[0063] [Figure 38-1] FIG. 38 shows the XRD pattern of the camsylate salt, Form II. [Figure 38-2] FIG. 38 shows the XRD pattern of the camsylate salt, Form II.
[0064] [Figure 39] FIG. 39 shows the DSC thermogram of the camsylate salt, Form II.
[0065] [Diagram 40] FIG. 40 shows the TGA-MS characterization of the camsylate salt, Form II.
[0066] [Figure 41-1] FIG. 41 shows the XRD pattern of the camsylate salt, Form III. [Figure 41-2] FIG. 41 shows the XRD pattern of the camsylate salt, Form III.
[0067] [Diagram 42] FIG. 42 shows the DSC thermogram of the camsylate salt, Form III.
[0068] [Diagram 43] FIG. 43 shows the overlay of the XRD patterns of the camsylate salt.
[0069] [Figure 44-1] FIG. 44 shows the XRD pattern of the Citrate Salt, Form I. [Figure 44-2] FIG. 44 shows the XRD pattern of the Citrate Salt, Form I.
[0070] [Diagram 45] FIG. 45 shows the DSC thermogram of the Citrate Salt, Form I.
[0071] [Diagram 46] FIG. 46 shows the TGA-MS characterization of the Citrate Salt, Form I.
[0072] [Figure 47] FIG. 47 shows the XRD pattern of the hydrochloride salt, Form I.
[0073] [Figure 48] FIG. 48 shows the DSC thermogram of the hydrochloride salt, Form I.
[0074] [Figure 49] FIG. 49 shows the TGA-MS characterization of the hydrochloride salt, Form I.
[0075] [Figure 50-1]FIG. 50 shows the XRD pattern of the hydrochloride salt, Form II. [Figure 50-2] FIG. 50 shows the XRD pattern of the hydrochloride salt, Form II.
[0076] [Figure 51] Figure 51 shows the DSC thermogram of the hydrochloride salt, Form II.
[0077] [Figure 52] FIG. 52 shows the TGA-MS characterization of the hydrochloride salt, Form II.
[0078] [Figure 53-1] FIG. 53 shows the XRD pattern of the hydrochloride salt, Form III. [Figure 53-2] FIG. 53 shows the XRD pattern of the hydrochloride salt, Form III.
[0079] [Figure 54-1] FIG. 54 shows the XRD pattern of naphthalene-1,5-disulfonic acid, Form I, where the bottom pattern is simulated based on single crystal data and the top trace is the X-ray diffraction powder pattern. [Figure 54-2] FIG. 54 shows the XRD pattern of naphthalene-1,5-disulfonic acid, Form I, where the bottom pattern is simulated based on single crystal data and the top trace is the X-ray diffraction powder pattern.
[0080] [Figure 55] FIG. 55 shows the solubility data for the free base and salt forms. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0081] Detailed Description (1S,3S)-N 1Polymorphic and salt forms of Compound A, also known as -(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine, are provided. Polymorphic forms of the free base of Compound A are provided, along with polymorphic forms of salts of Compound A, including tosylate, oxalate, fumarate, camsylate, citrate, hydrochloride, and naphthalene-1,5-disulfonate. Such forms have been characterized by X-ray diffraction (XRD), differential scanning calorimetry (DSC), and thermogravimetry-mass spectrometry (TGA-MS). Such polymorphic and salt forms can have desirable solubility, dissolution, and pharmacokinetic properties.
[0082] Before describing the present invention in more detail, it is to be understood that this invention is not limited to particular embodiments described, as such may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.
[0083] Where a range of values is provided, it is understood that each intervening value between the upper and lower limits of that range is also expressly disclosed, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise. Each smaller range between any stated value or intervening value in a stated range and any other stated value or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may be independently included or excluded in the range, and each range in which either or both of the limits are included in the smaller range, or neither limit is included in the smaller range, is also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where a stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0084] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Any methods and materials similar or equivalent to those described herein can be used in the practice or testing of this invention, but some possible exemplary methods and materials can be described below. Any publications mentioned herein are incorporated by reference to disclose and describe the methods and / or materials related to the cited publications. It is understood that this disclosure takes precedence over any disclosure of the incorporated publications to the extent of any discrepancy.
[0085] The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, a reference to "a droplet" includes a plurality of such droplets, a reference to "the individual entity" includes a reference to one or more individual entities, and so forth. It is further noted that the claims may be drafted to exclude any element, for example, any optional element. Thus, this statement is intended to serve as a predicate for the use of exclusive terminology such as "solely," "only," and the like or the use of a "negative" limitation in connection with the recitation of claim elements.
[0086] The publications discussed herein are provided solely for their disclosure prior to the filing date of this application.Furthermore, the publication dates provided may be different from the actual publication dates, which may need to be independently confirmed.To the extent that the definition or usage of any term herein conflicts with the definition or usage of the term in an application or reference incorporated herein by reference, this application shall control.
[0087] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has distinct components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the invention. Any recited method can be carried out in the order of events recited or in any other order which is logically possible. definition
[0088] The terms "polymorphic form," "polymorphic form," and "polymorph" are used interchangeably herein.
[0089] The term "AAC" refers to "accelerated aging conditions."
[0090] The terms active agent, active pharmaceutical ingredient, pharmacologically active agent, and drug are used interchangeably herein to refer to chemical substances or compounds that, when administered to an organism (human or animal), induce a desired pharmacological and / or physiological effect by local and / or systemic action.
[0091] The terms "individual", "host", "subject" and "patient" are used interchangeably herein and refer to animals including, but not limited to, human and non-human primates, including monkeys and humans; rodents, including rats and mice; cows; horses; sheep; cats; dogs, etc. "Mammal" means a member or members of any mammalian species, including, for example, dogs; cats; horses; cows; sheep; rodents, etc., and primates, such as non-human primates and humans. Non-human animal models, such as mammals, such as non-human primates, mice, rabbits, etc., may be used in experimental investigations.
[0092] As used herein, the terms "treatment", "treating" and the like refer to obtaining a desired pharmacological and / or physiological effect, such as reducing viral titers. The effect may be preventive in that it completely or partially prevents the disease or its symptoms, and / or may be therapeutic in that it partially or completely cures the disease and / or the harmful effects caused by the disease. As used herein, "treatment" encompasses any treatment of disease in a mammal, particularly a human, and includes (a) preventing the development of a disease or a symptom of a disease in a subject who may be susceptible to the disease but has not yet been diagnosed as having it (e.g., a disease that may be associated with or caused by a primary disease, such as in the case of liver fibrosis that may occur in the context of chronic HCV infection); (b) inhibiting the disease, i.e., preventing its development; and (c) relieving the disease, i.e., causing regression of the disease (e.g., reducing viral titers).
[0093] A "therapeutically effective amount," "therapeutically effective dose," or "therapeutic dose" is an amount sufficient to effect a desired clinical outcome (i.e., to achieve therapeutic efficacy, achieve a desired therapeutic response, etc.). A therapeutically effective dose can be administered in one or more administrations. For purposes of this disclosure, a therapeutically effective dose of a composition is an amount that, when administered to an individual, is sufficient to palliate, ameliorate, stabilize, reverse, prevent, slow or delay the progression of a disease condition (e.g., cancer, etc.) present in the subject.
[0094] As used herein, the terms "determining," "measuring," "assessing," and "assaying" are used interchangeably and include both quantitative and qualitative determinations.
[0095] The term "unit dosage form" as used herein refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of a compound (e.g., an aminopyrimidine compound described herein) calculated in an amount sufficient to produce the desired effect in association with a pharma- ceutically acceptable diluent, carrier, or vehicle. The specifications for the unit dosage forms depend on the particular compound employed and the effect to be achieved, as well as the pharmacodynamics associated with each compound in the host.
[0096] "Pharmaceutically acceptable excipients", "pharmaceutically acceptable diluents", "pharmaceutically acceptable carriers" and "pharmaceutically acceptable adjuvants" mean excipients, diluents, carriers and adjuvants that are generally safe, non-toxic and not biologically or otherwise undesirable and are useful in preparing pharmaceutical compositions, and include excipients, diluents, carriers and adjuvants that are acceptable for veterinary and human pharmaceutical use. "Pharmaceutically acceptable excipients, diluents, carriers and adjuvants" as used herein and in the claims includes both one and more than one such excipients, diluents, carriers and adjuvants. Carriers are generally described herein and further in "Remington's Pharmaceutical Sciences" by E.W. Martin.
[0097] As used herein, a "pharmaceutical composition" is intended to encompass a composition suitable for administration to a subject, e.g., a mammal, especially a human. Generally, a "pharmaceutical composition" is sterile and preferably free of contaminants that may induce an undesirable response within the subject (e.g., the compounds in the pharmaceutical composition are of pharmaceutical grade). A pharmaceutical composition may be designed for administration to a subject or patient in need thereof via a number of different administration routes, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, intrathecal, intramuscular, subcutaneous, and the like.
[0098] The terms "co-administration" and "in combination with" include administration of two or more therapeutic agents simultaneously, in parallel, or sequentially without a specific time limit. In one embodiment, the agents are present in a cell or in a subject's body at the same time or exert their biological or therapeutic effect at the same time. In one embodiment, the therapeutic agents are in the same composition or unit dosage form. In other embodiments, the therapeutic agents are in separate compositions or unit dosage forms. In certain embodiments, a first agent may be administered prior to (e.g., minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), in conjunction with, or after (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) administration of a second therapeutic agent. Salts and Polymorphic Forms
[0099] Polymorphic forms of the free base of Compound A are provided along with polymorphic forms of salts of Compound A. The free base of Compound A is represented by the formula (1S,3S)-N 1 It has the systematic IUPAC chemical name -(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine and formula (I): [ka] It has the chemical structure:
[0100] In some cases, the compound is the free base of Compound A. In other cases, the compound is a salt of Compound A, such as a salt selected from the group consisting of a tosylate, an oxalate, a fumarate, a camsylate, a citrate, a hydrochloride, and a naphthalene-1,5-disulfonate.
[0101] The free base or salt of Compound A can have a particular polymorphic form. In some cases, such forms can be characterized by X-ray diffraction (XRD), such as powder XRD or single crystal XRD. XRD can be used to determine the crystal structure of a polymorphic form or to determine that the form is amorphous. Such forms can also be characterized by differential scanning calorimetry (DSC) and thermogravimetry-mass spectrometry (TGA-MS). The results of DSC, sometimes referred to as a thermogram, can show how much heat is required to increase the temperature of a sample (e.g., a polymorphic form) compared to a reference material. In TGA-MS, a sample is heated and the change in mass is measured as a function of time and temperature (i.e., thermogravimetry). Additionally, the compounds liberated during heating are subjected to mass spectrometry.
[0102] In some cases, polymorphic forms of the free base or salts of Compound A have XRD, DSC, or TGA-MS spectra substantially as shown in the figures. As used herein, the term "substantially as shown" when referring to XRD, DSC, and TGA-MS is meant to encompass patterns or profiles that are not necessarily identical to those shown herein, but that fall within the limits of experimental error or variation when examined by one of ordinary skill in the art.
[0103] For XRD, experimental errors and deviations include the 2θ values of the peaks in the XRD spectrum. As an example, a given peak of a test sample can be located ±0.2° 2θ, such as ±0.1° 2θ, of the peak in the test sample. In some cases, the XRD pattern of the test sample has a peak that corresponds to the most intense peak in the reference spectrum. For example, the XRD pattern of the test sample can have four peaks located ±0.2° 2θ of the four most intense peaks of the reference XRD pattern, or six peaks located ±0.2° 2θ of the six most intense peaks.
[0104] For DSC, experimental error and deviation include the temperature of the peak in the DSC thermogram. As an example, a given peak of a test sample can be located within 20°C, e.g., within 10°C or within 5°C, of a reference peak. In some cases, the DSC thermogram of the test sample has one or more peaks that correspond to one or more peaks of maximum intensity in the reference thermogram. In some cases, the DSC thermogram has a single peak. It is understood that the "peak" in a DSC thermogram is usually a negative peak, e.g., the intensity decreases instead of increasing.
[0105] For TGA-MS, experimental error and deviation include the temperature of the peak in the thermogravimetric spectrum.In some cases, the thermogravimetric spectrum of the test sample has one or more peaks corresponding to the one or more peaks of maximum intensity in the reference thermogram, for example, two or more peaks corresponding to the two or more most intense peaks in the reference spectrum, or three or more peaks corresponding to the three or more most intense peaks in the reference spectrum.Experimental error and deviation also include the detection of a specific compound in the mass spectrum of TGA-MS analysis, which is measured by its m / z ratio.
[0106] Polymorphic forms I, II, and III of the free base of Compound A are provided. As used herein, "form I" is used interchangeably with "Form I" and "form II" is used interchangeably with "Form II." These forms can be characterized by XRD, DSC, and TGA-MS substantially as shown in Figures 1-6, 7A-7C, 8A-8C, and 9A-9C. The free base forms can be characterized by XRD peaks with 2θ values at the following values ±0.2° 2θ:
[0107] Form I: 10.0, 11.0, 13.3, 18.2, and 22.0
[0108] Form II: 7.2, 14.4, 21.7, and 22.5
[0109] Form III: Amorphous
[0110] Provided are polymorphic Forms I, II, III, and IV of the tosylate salt of Compound A. Such forms can be characterized by the XRD, DSC, and TGA-MS spectra shown in Figures 10-17. In some cases, the polymorphic forms of the tosylate salt have XRD peaks at the following values ±0.2° 2θ:
[0111] Form I: 5.1, 7.0, and 18.1
[0112] Form II: 5.2, 7.5, 18.1, 19.1, 20.6
[0113] Form III: 6.5, 15.4, 18.4, 21.8
[0114] Form IV: 5.4, 6.2, 15.7, 18.2
[0115] Provided are polymorphic Forms I, II, and III of the oxalate salt of Compound A. Such forms can be characterized by the XRD, DSC, and TGA-MS spectra shown in Figures 19-27. In some cases, the polymorphic forms of the oxalate salt have XRD peaks at the following values ±0.2° 2θ:
[0116] Form I: 4.1, 8.1, 12.2, and 19.6
[0117] Form II: 6.1, 8.2, 12.3, 19.6, 22.8
[0118] Form III: 10.8, 18.3, 19.9
[0119] Provided are polymorphic Forms I, II, III, IV, and V of the fumarate salt of Compound A. Such forms can be characterized by the XRD, DSC, and TGA-MS spectra shown in Figures 29-35. In some cases, the polymorphic forms of the fumarate salt have XRD peaks at the following values ±0.2° 2θ:
[0120] Form I: 4.2, 12.7, 18.7, 24.7
[0121] Form II: 4.3, 8.0, 11.5, 11.9, 24.5
[0122] Form III: 10.6, 11.5, 21.0 22.2, 24.6
[0123] Form IV: 3.9, 13.3, 23.3, 24.3
[0124] Form V:4.1, 12.4, 20.5, 21.0
[0125] Polymorphic Forms I, II, and III of the camsylate salt of Compound A are provided. The term "cas" is an abbreviation for camsylate salt. Such forms can be characterized by the XRD, DSC, and TGA-MS spectra shown in Figures 37-42. In some cases, the polymorphic forms of the camsylate salt have XRD peaks at the following values ±0.2° 2θ:
[0126] Form I: 4.8, 14.5, 16.8, 17.5, 20.2
[0127] Form II: 5.3, 12.6, 15.2, 17.2
[0128] Form III: 5.0, 12.2, 14.7, 23.0
[0129] Provided is polymorphic Form I of the citrate salt of Compound A. Such form can be characterized by the XRD, DSC, and TGA-MS spectra shown in Figures 44-46. In some cases, the polymorphic form of the citrate salt has XRD peaks at the following values ±0.2° 2θ:
[0130] Form I: 4.3, 8.0, 13.3, 20.8
[0131] Provided are polymorphic Forms I, II, and III of the hydrochloride salt of Compound A. Such forms can be characterized by the XRD, DSC, and TGA-MS spectra shown in Figures 47-53. In some cases, the polymorphic forms of the hydrochloride salt have XRD peaks at the following values ±0.2° 2θ:
[0132] Form I: Amorphous X-ray diffraction pattern
[0133] Form II: 9.9, 17.7, 21.3, 24.8
[0134] Form III: 9.4, 20.8, 22.7, 25.6
[0135] Provided is polymorphic Form I of naphthalene-1,5-disulfonate salt of Compound A. Such form can be characterized by the XRD, DSC, and TGA-MS spectra shown in Figure 54. In some cases, the polymorphic form of naphthalene-1,5-disulfonate salt has XRD peaks at the following values ±0.2° 2θ:
[0136] Form I: 8.3, 12.7, 13.1, 22.4, 24.1
[0137] In some cases, the compound is a monosalt, e.g., the compound comprises the structure of formula (I) and one equivalent of HCl. In other cases, the compound is a di-salt, e.g., the compound comprises the structure of formula (I) and two equivalents of HCl. The compound can also be a mono- or di-salt of tosylic acid, oxalic acid, fumaric acid, camsylic acid, citric acid, or naphthalene-1,5-disulfonic acid. The compound can also have a non-integer equivalent, e.g., 1.5 equivalents of HCl per molecule of formula (I) or 2.5 equivalents of HCl per molecule of formula (I). Methods for preparing polymorphic forms
[0138] Methods for synthesizing polymorphs of the tosylate, oxalate, fumarate, camsylate, citrate, hydrochloride, or naphthalene-1,5-disulfonate salts of Formula (I) are also provided.
[0139] In some cases, the method includes (i) contacting the free base of Formula (I) with a solvent and a compound that includes a tosylate, oxalate, fumarate, camsylate, citrate, chloride, or naphthalene-1,5-disulfonic acid moiety, thereby producing a composition that includes the solvent and the salt of Formula (I), and (ii) evaporating the solvent to produce a solid product.
[0140] In some cases, the compound containing the salt moiety is the corresponding acid. For example, in some cases, the compound is oxalic acid, in which case oxalic acid is deprotonated twice to obtain oxalate anion. Thus, the free base of compound A can be contacted with oxalic acid to obtain the protonated and cationic analog of formula (I) along with anionic oxalate ion. As another example, the compound can be naphthalene-1,5-disulfonic acid (also known as Armstrong acid), which can protonate the structure of formula (I) to form anionic naphthalene-1,5-disulfonic acid anion. Similarly, the compound can be camphorsulfonic acid to form camsylate salt, fumaric acid for fumarate salt, or citric acid for citrate salt.
[0141] Methods are provided for synthesizing polymorphs of the free base of Formula (I), such as Form I, Form II, or Form III. In some cases, the methods are for synthesizing Form III, such as by spray drying a solution of another form of the free base, such as Form I. As an example, the method can include spray drying a solution of Form I in methanol in the presence of particles such as, for example, PVP K30. Pharmaceutical Compositions
[0142] Provided is a pharmaceutical composition comprising the polymorph described herein and a pharma- ceutically acceptable carrier.In some cases, the pharmaceutical composition further comprises a pharma- ceutically acceptable additive, a pharma- ceutically acceptable diluent, a pharma- ceutically acceptable adjuvant, a pharma- ceutically acceptable disintegrant, a pharma- ceutically acceptable lubricant, or a combination thereof.In some cases, the pharmaceutical composition is an aqueous solution.In other embodiments, the pharmaceutical composition is a tablet or pill.
[0143] The pharmaceutical composition may be formulated to contain a suitable pharma- ceutically acceptable carrier, and may optionally include additives and auxiliary agents that facilitate processing of the polymorphic forms described herein into pharma- ceutical usable preparations. The mode of administration generally determines the nature of the carrier. For example, a formulation for parenteral administration may include an aqueous solution of the active compound in water-soluble form. Suitable carriers for parenteral administration may be selected from among physiological saline, buffered saline, dextrose, water, and other physiologically compatible solutions. Exemplary carriers for parenteral administration are physiologically compatible buffers, such as Hank's solution, Ringer's solution, or physiologically buffered saline. For tissue or cell administration, a penetrant appropriate for the particular barrier to be permeated is used in the formulation. Such penetrants are generally known in the art. For preparations containing proteins, the formulation may include stabilizing materials, such as polyols (e.g., sucrose) and / or surfactants (e.g., non-ionic surfactants), and the like.
[0144] Alternatively, formulations for parenteral use may include dispersions or suspensions of the polymorphic forms described herein prepared as suitable oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, and synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, dextran, and mixtures thereof. If necessary, the suspension may also contain suitable stabilizers, or agents that increase the solubility of the compounds, allowing for the preparation of highly concentrated solutions. Aqueous polymers that provide pH-sensitive solubilization and / or sustained release of the active agent, such as methacrylic polymers, such as EUDRAGIT available from Rohm America Inc. (Piscataway, NJ), may be used. TM Series can also be used as coating or matrix structure. Emulsions, such as oil-in-water dispersions and water-in-oil dispersions, can also be used, which can be stabilized by emulsifiers or dispersants (surface-active materials; surfactants) as necessary. Suspensions can contain suspending agents, such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tragacanth gum, and mixtures thereof.
[0145] Liposomes containing the polymorphic forms described herein can also be used for parenteral administration. Liposomes are generally derived from phospholipids or other lipid substances. The composition in the form of liposomes can also contain other components, such as stabilizers, preservatives, additives, and the like. Exemplary lipids include phospholipids and phosphatidylcholines (lecithins), both natural and synthetic. Methods for forming liposomes are known in the art. See, for example, Prescott (Ed.), Methods in Cell Biology, Vol. XIV, p. 33, Academic Press, New York (1976).
[0146] In some embodiments, the polymorphs disclosed herein or compositions thereof are formulated for oral administration using pharma- ceutically acceptable carriers known in the art. Preparations formulated for oral administration may be in the form of tablets, pills, capsules, cachets, dragees, lozenges, liquids, gels, syrups, slurries, elixirs, suspensions, or powders. For example, pharmaceutical preparations for oral use can be obtained by combining active compounds with solid additives, grinding the resulting mixture as necessary, and processing the mixture of granules to obtain tablets or dragee cores after adding suitable auxiliaries if desired. Oral preparations can use liquid carriers of the same type as those described for parenteral use, such as buffered aqueous solutions, suspensions, and the like.
[0147] Exemplary oral formulations include tablets, dragees, and gelatin capsules. These preparations may contain, but are not limited to, a) diluents such as microcrystalline cellulose and sugars, including lactose, dextrose, sucrose, mannitol, or sorbitol; b) binders such as sodium starch glycolate, croscarmellose sodium, magnesium aluminum silicate, starches derived from corn, wheat, rice, potato, etc.; c) cellulosic materials such as methylcellulose, hydroxypropylmethylcellulose, and sodium carboxymethylcellulose, polyvinylpyrrolidone, gums such as gum arabic and gum tragacanth, and proteins such as gelatin and collagen; d) cellulose derivatives such as cellulose acetate, cellulose acetate, cellulose esters such as cellulose acetate, cellulose acetate esters such as ... ) disintegrants or solubilizers, for example, cross-linked polyvinylpyrrolidone, starch, agar, alginic acid or a salt thereof, for example, sodium alginate, or an effervescent composition; e) lubricants, for example, silica, talc, stearic acid or its magnesium or calcium salts, and polyethylene glycol; f) flavorants and sweeteners; g) colorants or pigments, for example, for identifying the product or for characterizing the quantity (dosage) of active compound; and h) other ingredients, which may contain one or more additives including, for example, preservatives, stabilizers, swelling agents, emulsifiers, solution enhancers, salts for regulating osmotic pressure, and buffers.
[0148] Examples of carriers include, but are not limited to, aluminum monostearate, aluminum stearate, carboxymethylcellulose, sodium carboxymethylcellulose, crospovidone, glyceryl isostearate, glyceryl monostearate, hydroxyethylcellulose, hydroxymethylcellulose, hydroxyoctacosanyl hydroxystearate, hydroxypropylcellulose, hydroxypropylmethylcellulose, lactose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 188, poloxamer 237, poloxamer 407, povidone, silicon dioxide, colloidal silicon dioxide, silicone, silicone adhesive 4102, and silicone emulsion. However, it should be understood that the carrier selected for the pharmaceutical composition provided in the present disclosure, and the amount of such carrier in the composition, may vary depending on the formulation method (e.g., dry granulation formulation, solid dispersion formulation).
[0149] In one particular variation, the pharmaceutical composition comprises a polymorph as described herein and at least one pharma- ceutically acceptable carrier selected from the group consisting of hydroxypropylmethylcellulose, mannitol, crospovidone, poloxamer, colloidal silicon dioxide, microcrystalline cellulose, magnesium stearate, and any mixture thereof. In another variation, the pharmaceutical composition comprises a polymorph as described herein and at least one additional pharma- ceutically acceptable carrier selected from the group consisting of hydroxypropylmethylcellulose, mannitol, crospovidone, poloxamer, colloidal silicon dioxide, microcrystalline cellulose, magnesium stearate, and any mixture thereof.
[0150] Regardless of the route of administration selected, the agents / compounds of the present disclosure may be formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those of skill in the art using pharma- ceutically acceptable carriers well known in the art (see, e.g., Remington, The Science and Practice of Pharmacy (21st Edition, Lippincott Williams and Wilkins, Philadelphia, Pa.) and The National Formulary (American Pharmaceutical Association, Washington, DC)), sugars (e.g., lactose, sucrose, mannitol, and sorbitol), starches, cellulose preparations, calcium phosphates (e.g., dicalcium phosphate, tricalcium phosphate, and dibasic calcium phosphate), sodium citrate, water, aqueous solutions (e.g., saline, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, lactated Ringer's injection), alcohols (e.g., ethyl alcohol, propyl alcohol, and benzyl alcohol), polyols (e.g., glycols, glycerol ... glycerol, propylene glycol, and polyethylene glycol), organic esters (e.g., ethyl oleate and triglycerides), biodegradable polymers (e.g., polylactide-polyglycolide, poly(orthoesters), and poly(anhydrides)), elastomeric matrices, liposomes, microspheres, oils (e.g., corn oil, germ oil, olive oil, castor oil, sesame oil, cottonseed oil, and peanut oil), cocoa butter, waxes (e.g., suppository wax), paraffin, silicones, talc, silicylate, and the like. Each of the pharma- ceutically acceptable carriers used in the pharmaceutical compositions of the present disclosure is "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject. Carriers suitable for a selected dosage form and intended route of administration are well known in the art, and acceptable carriers for a selected dosage form and method of administration can be determined using ordinary skill in the art.
[0151] The pharmaceutical compositions of the present disclosure may optionally contain additional ingredients and / or materials that are commonly used in such pharmaceutical compositions. These ingredients and materials are well known in the art and include (1) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (2) binders, such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, hydroxypropylmethylcellulose, sucrose, and acacia; (3) humectants, such as glycerol; (4) disintegrants, such as agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, sodium starch glycolate, cross-linked sodium carboxymethylcellulose, and sodium carbonate; (5) solution retarders. (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as cetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, and sodium lauryl sulfate; (10) suspending agents, such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, and tragacanth; (11) buffering agents; (12) additives, such as lactose, milk sugar, polyethylene glycol, animal fats, and and vegetable fats, oils, waxes, paraffin, cocoa butter, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc, salicylates, zinc oxide, aluminum hydroxide, calcium silicate, and polyamide powders;(13) inert diluents, such as water or other solvents;(14) preservatives;(15) surface active agents;(16) dispersing agents;(17) controlled-release or absorption retarding agents, such as hydroxypropyl methylcellulose, other polymer matrices, biodegradable polymers, liposomes, microspheres, aluminum monostearate, gelatin, and waxes;(18) opacifying agents;(19) adjuvants;(20) wetting agents;(21) emulsifying and suspending agents;(22) solubilizing and emulsifying agents, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol, and fatty acid esters of sorbitan; (23) propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane; (24) antioxidants; (25) agents that render the formulation isotonic with the blood of the intended recipient, such as sugars and sodium chloride; (26) thickening agents; (27) coating materials, such as lecithin; and (28) sweetening agents, flavoring agents, coloring agents, fragrances, and preservatives. Each such ingredient or material must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject. Ingredients and materials suitable for a selected dosage form and intended route of administration are well known in the art, and acceptable ingredients and materials for a selected dosage form and method of administration can be determined using ordinary skill in the art.
[0152] Pharmaceutical compositions suitable for oral administration may be in the form of a capsule, cachet, pill, tablet, powder, granules, a solution or suspension in an aqueous or non-aqueous liquid, an oil-in-water or water-in-oil liquid emulsion, an elixir or syrup, a troche, a bolus, a electuary, or a paste. These formulations may be prepared by methods known in the art, for example, using conventional pan-coating, mixing, granulating, or lyophilizing processes.
[0153] Solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules, etc.) can be prepared, for example, by mixing the active ingredient with one or more pharma- ceutically acceptable carriers and, if necessary, one or more fillers, extenders, binders, humectants, disintegrants, dissolution inhibitors, absorption accelerators, wetting agents, absorbents, lubricants, and / or colorants. Solid compositions of a similar type can be used as fillers in soft and hard-filled gelatin capsules, using suitable additives. Tablets can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared using suitable binders, lubricants, inert diluents, preservatives, disintegrants, surface active or dispersing agents. Molded tablets can be made by molding in a suitable machine. Tablets, and other solid dosage forms, such as dragees, capsules, pills, and granules, can be optionally scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the art of pharmaceutical formulation. They can also be formulated to provide slow or controlled release of the active ingredient therein. They can be sterilized, for example, by filtration through a bacteria-retaining filter. These compositions can also optionally contain opacifying agents, and can be of a composition that releases the active ingredient only or preferentially in a certain part of the gastrointestinal tract, optionally in a delayed manner. The active ingredient can also be in microencapsulated form.
[0154] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.Liquid dosage forms can contain suitable inert diluents that are commonly used in the art.Besides inert diluents, oral compositions can also contain adjuvants, such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents, coloring agents, aromatic agents and preservatives.Suspensions can contain suspending agents.
[0155] The pharmaceutical composition for rectal or vaginal administration may be provided as a suppository, which can be prepared by mixing one or more active ingredients with one or more suitable non-irritating carriers that are solid at room temperature but liquid at body temperature, and therefore melt in the rectum or vaginal cavity and release the active compound.The pharmaceutical composition suitable for vaginal administration also includes pessaries, tampons, creams, gels, pastes, foams or spray formulations that contain pharma- ceutical acceptable carriers as known in the art to be suitable.
[0156] The dosage form for topical or transdermal administration includes powder, spray, ointment, paste, cream, lotion, gel, solution, patch, drop and inhalant.The active agent / compound can be mixed with suitable pharmaceutically acceptable carrier under sterile conditions.Ointment, paste, cream and gel can contain additives.Powder and spray can contain additives and propellants.
[0157] Pharmaceutical compositions suitable for parenteral administration include one or more agents / compounds in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders that can be reconstituted immediately before use into sterile injectable solutions or dispersions, which may contain suitable antioxidants, buffers, solutes that make the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents. Proper fluidity can be maintained, for example, by using coating materials, by maintaining the required particle size in the case of dispersions, and by using surfactants. These compositions may also contain suitable adjuvants, such as wetting agents, emulsifying agents, and dispersing agents. It may also be desirable to include an isotonic agent. In addition, sustained absorption of injectable pharmaceutical forms can be brought about by including agents that delay absorption.
[0158] In some cases, in order to prolong the effect of a drug (e.g., pharmaceutical formulation), it is desirable to slow its absorption from subcutaneous or intramuscular injection. This can be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility.
[0159] As a result, the rate of absorption of the active agent / drug depends on its rate of dissolution, which in turn may depend on the crystal size and crystalline form. Alternatively, delayed absorption of parenterally administered agents / drugs can be achieved by dissolving or suspending the active agent / drug in an oil vehicle. Injectable depot forms can be made by forming microencapsulated matrices of the active ingredient in biodegradable polymers. Depending on the ratio of active ingredient to polymer and the nature of the particular polymer used, the rate of active ingredient release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues. The injectable material can be sterilized, for example, by filtration through a bacteria-retaining filter.
[0160] The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier, for example, water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the type described above. How to use
[0161] Methods of treating a condition in a subject are provided by administering to the subject a polymorph as described herein or a pharmaceutical composition as described herein that includes such a polymorph. In some cases, the condition is cancer or an autoimmune disease. In some embodiments, the subject is a human, e.g., a human with cancer or an autoimmune disease. In some cases, the method is carried out using a kit as described herein.
[0162] The pharmaceutical compositions of the present disclosure may be administered in any desired and effective manner, such as for oral ingestion or as ointments or drops for topical administration to the eye, or for parenteral or other administration in any suitable manner, such as intraperitoneal, subcutaneous, topical, intradermal, inhalation, pulmonary, rectal, vaginal, sublingual, intramuscular, intravenous, intraarterial, intrathecal, or intralymphatic.Furthermore, the pharmaceutical compositions of the present disclosure may be administered in combination with other treatments.The pharmaceutical compositions of the present disclosure may be encapsulated or otherwise protected from gastric or other secretions, if desired.
[0163] Suitable non-limiting examples of dosages of compounds according to the present disclosure are from about 1 ng / kg to about 1000 mg / kg, for example, from about 1 mg / kg to about 100 mg / kg, including from about 5 mg / kg to about 50 mg / kg. Other representative dosages of PI3K inhibitors include about 1 mg / kg, 5 mg / kg, 10 mg / kg, 15 mg / kg, 20 mg / kg, 25 mg / kg, 30 mg / kg, 35 mg / kg, 40 mg / kg, 45 mg / kg, 50 mg / kg, 60 mg / kg, 70 mg / kg, 80 mg / kg, 90 mg / kg, 100 mg / kg, 125 mg / kg, 150 mg / kg, 175 mg / kg, 200 mg / kg, 250 mg / kg, 300 mg / kg, 400 mg / kg, 500 mg / kg, 600 mg / kg, 700 mg / kg, 800 mg / kg, 900 mg / kg, or 1000 mg / kg. kit
[0164] Kits are provided that include a polymorph as described herein, or a pharmaceutical composition comprising such a polymorph, and instructions for using the polymorph or pharmaceutical composition. In some cases, the instructions instruct a user to administer the polymorph or pharmaceutical composition to a subject having a condition, e.g., cancer or an autoimmune disorder. In some cases, the instructions instruct administration by oral administration, injection, or any other suitable route of administration. In some cases, the subject is a human. The instructions can instruct administration according to any of the features described in the Method of Use section above. The instructions can have any suitable format, e.g., printed on a label or stored in electronic form on an electronic storage medium, such as a universal serial (USB) storage device. EXAMPLES
[0165] The following examples are presented so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the invention, and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent that the experiments described below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure. Standard abbreviations may be used, such as s or sec, seconds; min, minutes; h or hr, hours, etc. Experimental Method
[0166] The horizontal axis of the DSC (differential scanning calorimetry) thermograms in the figures is from 25 to 300° C. unless otherwise specified. For the TGA-MS (thermogravimetry-mass spectrometry) in the figures, the graph starting higher is the sample weight and the graph starting lower is the heat flow.
[0167] TGA / SDTA and TGA-MS analysis:
[0168] Mass loss due to loss of solvent or water from the crystals was determined by TGA / DSC. Weight vs. temperature curves and heat flow signals were obtained by monitoring sample weight during heating in a TGA / DSC 3+ STARe system (Mettler-Toledo GmbH, Switzerland). The TGA / DSC 3+ was calibrated for temperature with samples of indium and aluminum. Samples (approximately 1 mg) were weighed into 100 μL aluminum crucibles and sealed. A pinhole was drilled in the lid and the crucibles were heated in the TGA from 25° C. to 300° C. at a heating rate of 10° C. / min. Dry N2 gas was used for purging.
[0169] Gases from the TGA samples were analyzed by a mass spectrometer Omnistar GSD 301 T2 (Pfeiffer Vacuum GmbH, Germany), which is a quadrupole mass spectrometer that analyzes masses in the m / z range of 0–200 amu.
[0170] DSC analysis:
[0171] Thermal events were obtained from DSC thermograms recorded on a heat flux DSC3+ STARe system (Mettler-Toledo GmbH, Switzerland). The DSC3+ was calibrated for temperature and enthalpy with indium (melting point = 156.6 °C; δHf = 28.45 J / g) and zinc (melting point = 419.6 °C; δHf = 107.5 J / g). Samples (approximately 1 mg) were sealed in standard 40 μL aluminum pans, pinhole drilled, and heated in the DSC from 25 °C to 300 °C at a heating rate of 10 °C / min unless otherwise specified. Dry N2 gas was used at a flow rate of 50 mL / min to purge the DSC instrument during the measurements.
[0172] HPLC analysis:
[0173] Details regarding the HPLC analysis for assay and purity determination are provided in separate publications. An overview of the HPLC method is provided in the table below. [Table 1] [Table 2]
[0174] pH determination:
[0175] pH was recorded with a Metrohm 913 pH meter equipped with a WTW SenTix® MIC-B electrode.
[0176] Dynamic Vapor Sorption:
[0177] Moisture sorption isotherms were collected on a DVS-1 system from Surface Measurement Systems (London, UK). A sample size of approximately 8 mg of solid material was used. The material was subjected to a relative humidity profile of 40-95-0-40% RH with a 10% increase in RH level per step. Weight equilibration times were set at a minimum of 60 min and a maximum hold time of 6 h per relative humidity step with a dm / dt of 0.002% / min. Example 1 Synthesis of the free base of compound A
[0178] The precursor of Compound A was prepared according to the procedures of U.S. Patent Application Publication No. 2020 / 0131189, which is incorporated herein by reference.
[0179] Preparation of Form I: HCl and precursor are added to a reactor and stirred at 20°C to 25°C until the reaction shows less than 0.5% precursor remaining as monitored by HPLC. The pH of the reaction mixture is adjusted to 6 to 7 with 48% aqueous NaOH and methyl tert-butyl ether (MTBE) is added. The pH is then further adjusted to pH=14 with 48% aqueous NaOH and the layers are separated. The aqueous layer is back extracted with MTBE and the combined organic layers are washed with water. The MTBE solution is then partially concentrated under atmospheric pressure to remove residual water and then cooled to 20°C to 25°C. The solution is polish filtered and the filtrate is concentrated and coevaporated with n-heptane. The residue is then dissolved in n-heptane at 95°C to 100°C and then slowly cooled to 20°C to 25°C to crystallize the product. The material is collected by filtration, washed with n-heptane and then dried to obtain the free base Form 1 of Compound I. The morphology was characterized by XRD, DSC, and TGA-MS as shown in Figures 1 - 3 .
[0180] Form II generation: Form I of the free base was dissolved in a solvent, frozen in liquid nitrogen, and then freeze-dried in vacuum for 18 hours (Alpha 2-4 LD, Martin Christ). Alternatively, Form I was dissolved in a solvent and the solvent was allowed to slowly evaporate. As shown in the table below, such methods resulted in the regeneration of Form I, the generation of Form II, the generation of a mixture of Forms I and II, or an amorphous product. Form II was characterized by XRD, DSC, and TGA-MS as shown in Figures 4-6. XRPD refers to X-ray powder diffraction. [Table 3]
[0181] Form III Generation:
[0182] An initial attempt to generate an amorphous form of the free base was performed by slow evaporation of a solution of Form I. In particular, Form I was dissolved in ethanol according to the chart below and then slowly evaporated. [Table 4]
[0183] The resulting product was physically observed to be an oil, and XRD indicated that the product was amorphous. However, when additional XRD characterization was performed after about 45 minutes, it was observed that the amorphous product had begun to crystallize. Figure 7D shows the initial XRD (bottom) and the XRD after about 45 minutes (top).
[0184] Subsequent attempts to create an amorphous form of the free base used spray drying. PVP K30 (Kollidon 30) was stirred in MeOH at room temperature until a solution was obtained. Compound A free base Form I was then added to the solution and stirred to dissolve. The ratio of free base Form I to PVP K30 in MeOH is shown in the table below. Spray drying parameters are shown in another table below. It was found that spray drying resulted in a crystalline form assigned as Form III. [Table 5] [Table 6] Example 2 Tosylate of Compound A
[0185] The synthesis of the tosylate salt began with mixing the free base form I and a 1 M aqueous solution of the counterion (tosylate) in water / t-butanol (1:9, v / v). The mixture was then frozen in liquid nitrogen and lyophilized for 18 h in a freeze dryer (Alpha 2-4 LD, Martin Christ).
[0186] The resulting solid was then combined with another solvent (acetonitrile (AcN) or ethanol) and the resulting mixture was stirred at room temperature (RT). After stirring, the solid was isolated by centrifugation and a portion of the solid was collected in a 96-well plate and dried under ambient conditions. The remaining portion of the solid was dried under vacuum (5 mbar [i.e., 500 Pa], room temperature, 18 h). All solids were analyzed by XRPD and subjected to accelerated aging conditions (AAC; 40 °C / 75% RH) and reanalyzed by XRPD. The procedures and resulting tosylate salt forms are shown in the table below, where the forms were identified by XRD. The characteristics of these forms are shown in Figures 10-18. [Table 7] Example 3 Compound A oxalate
[0187] The oxalate salt was prepared in a similar manner to the tosylate salt.
[0188] The synthesis of the oxalate salt began with mixing the free base form I and a 1 M aqueous solution of the counterion (oxalate) in water / t-butanol (1:9, v / v). The mixture was then frozen in liquid nitrogen and lyophilized for 18 h in a freeze dryer (Alpha 2-4 LD, Martin Christ).
[0189] The resulting solid was then combined with another solvent (acetonitrile (AcN) or chloroform) and the resulting mixture was stirred at room temperature (RT). After stirring, the solid was isolated by centrifugation and a portion of the solid was collected in a 96-well plate and dried under ambient conditions. The remaining portion of the solid was dried under vacuum (5 mbar, room temperature, 18 h). All solids were analyzed by XRPD, subjected to AAC (accelerated aging conditions; 40 °C / 75% RH) and reanalyzed by XRPD. Methods and results are summarized in the table below and characteristics are shown in Figures 19-28. [Table 8] Example 4 Fumarate salt of compound A
[0190] The fumarate salt was prepared in a similar manner to the tosylate salt.
[0191] The synthesis of the fumarate salt began with mixing the free base form I and a 1 M aqueous solution of the counterion (fumarate) in water / t-butanol (1:9, v / v). The mixture was then frozen in liquid nitrogen and lyophilized for 18 h in a freeze dryer (Alpha 2-4 LD, Martin Christ).
[0192] The resulting solid was then combined with another solvent (AcN, diethyl ether, or toluene) and the resulting mixture was stirred at room temperature (RT). After stirring, the solid was isolated by centrifugation and a portion of the solid was collected in a 96-well plate and dried under ambient conditions. The remaining portion of the solid was dried under vacuum (5 mbar, RT, 18 h). All solids were analyzed by XRPD, subjected to AAC (40 °C / 75% RH) and reanalyzed by XRPD. Methods and results are summarized in the table below and characteristics are shown in Figures 29-36. [Table 9] Example 5 Compound A camsylate salt
[0193] The camsylate salt was prepared in a similar manner to the tosylate salt.
[0194] The synthesis of the camsylate salt began with mixing the free base form I and a 1 M aqueous solution of the counterion (camsylate) in water / t-butanol (1:9, v / v). The mixture was then frozen in liquid nitrogen and lyophilized for 18 h in a freeze dryer (Alpha 2-4 LD, Christ).
[0195] The resulting solid was then combined with another solvent (1,4-dioxane, acetonitrile, ethyl acetate) and the resulting mixture was stirred at room temperature (RT). After stirring, the solid was isolated by centrifugation and a portion of the solid was collected in a 96-well plate and dried under ambient conditions. The remaining portion of the solid was dried under vacuum (5 mbar, RT, 18 h). All solids were analyzed by XRPD, subjected to AAC (40 °C / 75% RH) and reanalyzed by XRPD. Methods and results are summarized in the table below and characteristics are shown in Figures 37-43. [Table 10]
[0196] Form I (single crystal) was prepared by dissolving 20-30 mg of Compound A in 100 μl of dioxane followed by addition of camsylate counterion in 300 μl of dioxane. After a solution was obtained, the mixture was left open to slowly evaporate. Example 6 Compound A citrate
[0197] The citrate salt was prepared in a similar manner to the tosylate salt.
[0198] The synthesis of the citrate salt began with mixing the free base Form I and a 1 M aqueous solution of the counterion (citrate) in water / t-butanol (1:9, v / v). The mixture was then frozen in liquid nitrogen and lyophilized for 18 h in a freeze dryer (Alpha 2-4 LD, Christ).
[0199] The resulting solid was then combined with another solvent (acetonitrile or ethyl acetate) and the resulting mixture was stirred at room temperature (RT). After stirring, the solid was isolated by centrifugation and a portion of the solid was collected in a 96-well plate and dried under ambient conditions. The remaining portion of the solid was dried under vacuum (5 mbar, room temperature, 18 h). All solids were analyzed by XRPD, subjected to AAC (40 °C / 75% RH) and reanalyzed by XRPD. Methods and results are summarized in the table below and characteristics are shown in Figures 44-46. [Table 11] Example 7 Compound A hydrochloride
[0200] The hydrochloride salt was prepared in a similar manner to the tosylate salt.
[0201] The synthesis of the hydrochloride salt began with mixing the free base form I and a 1 M aqueous solution of the counterion (chloride) in water / t-butanol (1:9, v / v). The mixture was then frozen in liquid nitrogen and lyophilized for 18 h in a freeze dryer (Alpha 2-4 LD, Christ).
[0202] The resulting solid was then combined with another solvent (acetonitrile or diethyl ether) and the resulting mixture was stirred at room temperature (RT). After stirring, the solid was isolated by centrifugation and a portion of the solid was collected in a 96-well plate and dried under ambient conditions. The remaining portion of the solid was dried under vacuum (5 mbar, RT, 18 h). All solids were analyzed by XRPD, subjected to AAC (40 °C / 75% RH) and reanalyzed by XRPD. Methods and results are summarized in the table below and characteristics are shown in Figures 47-53. [Table 12] Example 8 Naphthalene-1,5-disulfonate of compound A
[0203] Naphthalene-1,5-disulfonate salt was prepared by dissolving 20-30 mg of compound I in 100 μL of water in an 8 ml vial. One equivalent of counter ion (Nds) was added in 300 μL of the aqueous solution at room temperature. The vial was sealed and shaken for 30 seconds, after which it was left open for several days to evaporate. The solid was characterized by XRD as shown in Figure 54. Example 9 Solubility of the free base and salt forms of Compound A
[0204] As shown in the table below, salts of Compound A exhibit various degrees of enhanced solubility in physiological conditions, making them suitable for formulation development of different immediate and modified release oral dosage formulations. FaSSGF is fasted state simulated gastric fluid. Solubility is reported in mg / mL. [Table 13]
[0205] As shown above, the aqueous solubility of the free base was 5.9 mg / ml, whereas increased solubility was observed for the tosylate, oxalate, fumarate, camsylate, and citrate forms studied.
[0206] Terms Notwithstanding the scope of the appended claims, the present disclosure is also defined by the following clauses. 1. Formula (I): [ka] Polymorphism of the free base of. 2. The polymorph of clause 1, wherein said polymorph has Form I. 3. The polymorph described in clause 2, characterized by an X-ray diffraction (XRD) pattern containing 2θ peaks at 10.0, 11.0, 13.3, 18.2, and 22.0±0.2 degrees 2θ. 4. The polymorph of any one of clauses 2 to 3, characterized by an XRD pattern substantially as shown in Figure 1. 5. The polymorph of any one of clauses 2 to 4, characterized by a differential scanning calorimetry (DSC) thermogram substantially as shown in Figure 2. 6. The polymorph of any one of clauses 2 to 5, characterized by a thermogravimetric-mass spectrometry (TGA-MS) spectrum substantially as shown in FIG. 3. 7. The polymorph according to clause 1, wherein said polymorph has Form II. 8. The polymorph of clause 7, characterized by an XRD pattern containing 2θ peaks at 7.2, 14.4, 21.7, and 22.5±0.2 degrees 2θ. 9. The polymorph of any one of clauses 7 to 8, characterized by an XRD pattern substantially as shown in Figure 4. 10. The polymorph of any one of clauses 7 to 9, characterized by a DSC thermogram substantially as shown in Figure 5. 11. The polymorph of any one of clauses 7 to 10, characterized by a TGA-MS spectrum substantially as shown in Figure 6. 12. The polymorph according to clause 1, wherein the polymorph has Form III. 13. The polymorph according to clause 12, characterized by an amorphous XRD pattern. 14. The polymorph of any one of clauses 12-13, characterized by an XRD pattern substantially as shown in Figure 7A, 8A, or 9A. 15. The polymorph of any one of clauses 12 to 14, characterized by a DSC thermogram substantially as shown in Figure 7B, 8B, or 9B. 16. The polymorph of any one of clauses 7 to 10, characterized by a TGA-MS spectrum substantially as shown in Figure 7C, 8C, or 9C. 17. Formula (I): [ka] Polymorphism of the tosylate salt of . 18. The polymorph according to clause 17, wherein said polymorph has Form I. 19. The polymorph of clause 18, characterized by an XRD pattern containing 2θ peaks at 5.1, 7.0, and 18.1±0.2 degrees 2θ. 20. The polymorph of any one of clauses 18 to 19, characterized by an XRD pattern substantially as shown in Figure 10. 21. The polymorph of any one of clauses 18 to 20, characterized by a DSC thermogram substantially as shown in Figure 11. 22. The polymorph of any one of clauses 18 to 21, characterized by a TGA-MS spectrum substantially as shown in Figure 12. 23. The polymorph according to clause 17, wherein said polymorph has Form II. 24. The polymorph of clause 23, characterized by an XRD pattern containing 2θ peaks at 5.2, 7.5, 18.1, 19.1, and 20.6±0.2 degrees 2θ. 25. The polymorph of any one of clauses 23-24, characterized by an XRD pattern substantially as shown in FIG. 13. 26. The polymorph according to clause 17, wherein said polymorph has Form III. 27. The polymorph of clause 26, characterized by an XRD pattern containing 2θ peaks at 6.5, 15.4, 18.4, and 21.8±0.2 degrees 2θ. 28. The polymorph of any one of clauses 26 to 27, characterized by an XRD pattern substantially as shown in Figure 14. 29. The polymorph of any one of clauses 26 to 28, characterized by a DSC thermogram substantially as shown in Figure 15. 30. The polymorph of any one of clauses 26 to 29, characterized by a TGA-MS spectrum substantially as shown in Figure 16. 31. The polymorph according to clause 17, wherein said polymorph has Form IV. 32. The polymorph of clause 31, characterized by an XRD pattern containing 2θ peaks at 5.4, 6.2, 15.7, and 18.2±0.2 degrees 2θ. 33. The polymorph of any one of clauses 31 to 32, characterized by an XRD pattern substantially as shown in FIG. 17. 34. Formula (I): [ka] Polymorphism of the oxalate salt of. 35. The polymorph according to clause 34, wherein said polymorph has Form I. 36. The polymorph of clause 35, characterized by an XRD pattern containing 2θ peaks at 4.1, 8.1, 12.2, and 19.6±0.2 degrees 2θ. 37. The polymorph of any one of clauses 35 to 36, characterized by an XRD pattern substantially as shown in FIG. 19. 38. The polymorph of any one of clauses 35 to 37, characterized by a DSC thermogram substantially as shown in Figure 20. 39. The polymorph of any one of clauses 35 to 38, characterized by a TGA-MS spectrum substantially as shown in Figure 21. 40. The polymorph according to clause 34, wherein said polymorph has Form II. 41. The polymorph of clause 40, characterized by an XRD pattern containing 2θ peaks at 6.1, 8.2, 12.3, 19.6, and 22.8±0.2 degrees 2θ. 42. The polymorph of any one of clauses 40 to 41, characterized by an XRD pattern substantially as shown in FIG. 22. 43. The polymorph of any one of clauses 40 to 42, characterized by a DSC thermogram substantially as shown in Figure 23. 44. The polymorph of any one of clauses 40 to 43, characterized by a TGA-MS spectrum substantially as shown in Figure 24. 45. The polymorph according to clause 34, wherein said polymorph has Form III. 46. The polymorph of clause 45, characterized by an XRD pattern containing 2θ peaks at 10.8, 18.3, and 19.9±0.2 degrees 2θ. 47. The polymorph of any one of clauses 45 to 46, characterized by an XRD pattern substantially as shown in FIG. 25. 48. The polymorph of any one of clauses 45 to 47, characterized by a DSC thermogram substantially as shown in Figure 26. 49. The polymorph of any one of clauses 45 to 48, characterized by a TGA-MS spectrum substantially as shown in Figure 27. 50. Formula (I): [ka] Polymorphism of the fumarate salt of . 51. The polymorph according to clause 50, wherein said polymorph has Form I. 52. The polymorph of clause 51, characterized by an XRD pattern containing 2θ peaks at 4.2, 12.7, 18.7, and 24.7±0.2 degrees 2θ. 53. The polymorph of any one of clauses 51 to 52, characterized by an XRD pattern substantially as shown in FIG. 29. 54. The polymorph according to clause 50, wherein said polymorph has Form II. 55. The polymorph of clause 54, characterized by an XRD pattern containing 2θ peaks at 4.3, 8.0, 11.5, 11.9, and 24.5±0.2 degrees 2θ. 56. The polymorph of any one of clauses 54 to 55, characterized by an XRD pattern substantially as shown in Figure 30. 57. The polymorph according to clause 50, wherein said polymorph has Form III. 58. The polymorph of clause 57, characterized by an XRD pattern containing 2θ peaks at 10.6, 11.5, 21.0 22.2, and 24.6±0.2 degrees 2θ. 59. The polymorph of any one of clauses 57-58, characterized by an XRD pattern substantially as shown in FIG. 31. 60. The polymorph of any one of clauses 57 to 59, characterized by a DSC thermogram substantially as shown in Figure 32. 61. The polymorph of any one of clauses 57 to 60, characterized by a TGA-MS spectrum substantially as shown in Figure 33. 62. The polymorph according to clause 50, wherein said polymorph has Form IV. 63. The polymorph of clause 62, characterized by an XRD pattern containing 2θ peaks at 3.9, 13.3, 23.3, and 24.3±0.2 degrees 2θ. 64. The polymorph of any one of clauses 62 to 63, characterized by an XRD pattern substantially as shown in Figure 34. 65. The polymorph according to clause 50, wherein said polymorph has Form V. 66. The polymorph of clause 65, characterized by an XRD pattern containing 2θ peaks at 4.1, 12.4, 20.5, and 21.0±0.2 degrees 2θ. 67. The polymorph of any one of clauses 65 to 66, characterized by an XRD pattern substantially as shown in Figure 35. 68. Formula (I): [ka] Polymorphism of the camsylate salt of . 69. The polymorph according to clause 68, wherein said polymorph has Form I. 70. The polymorph of clause 69, characterized by an XRD pattern containing 2θ peaks at 4.8, 14.5, 16.8, 17.5, and 20.2±0.2 degrees 2θ. 71. The polymorph of any one of clauses 69-70, characterized by an XRD pattern substantially as shown in Figure 37. 72. The polymorph according to clause 68, wherein said polymorph has Form II. 73. The polymorph of clause 72, characterized by an XRD pattern containing 2θ peaks at 5.3, 12.6, 15.2, 17.2, and 19.7±0.2 degrees 2θ. 74. The polymorph of any one of clauses 72-73, characterized by an XRD pattern substantially as shown in Figure 38. 75. The polymorph of any one of clauses 72 to 74, characterized by a DSC thermogram substantially as shown in Figure 39. 76. The polymorph of any one of clauses 72 to 75, characterized by a TGA-MS spectrum substantially as shown in Figure 40. 77. The polymorph according to clause 68, wherein said polymorph has Form III. 78. The polymorph of clause 77, characterized by an XRD pattern containing 2θ peaks at 5.0, 12.2, 14.7, and 23.0±0.2 degrees 2θ. 79. The polymorph of any one of clauses 77-78, characterized by an XRD pattern substantially as shown in Figure 41. 80. The polymorph of any one of clauses 77 to 79, characterized by a DSC thermogram substantially as shown in Figure 42. 81. Formula (I): [ka] Polymorphs of the citrate salt of . 82. The polymorph according to clause 81, wherein said polymorph has Form I. 83. The polymorph of clause 82, characterized by an XRD pattern containing 2θ peaks at 4.3, 8.0, 13.3, and 20.8±0.2 degrees 2θ. 84. The polymorph of any one of clauses 82-83, characterized by an XRD pattern substantially as shown in Figure 44. 85. The polymorph of any one of clauses 82 to 84, characterized by a DSC thermogram substantially as shown in Figure 45. 86. The polymorph of any one of clauses 82 to 85, characterized by a TGA-MS spectrum substantially as shown in Figure 46. 87. Formula (I): [ka] Polymorphism of the hydrochloride salt of. 88. The polymorph according to clause 87, wherein said polymorph has Form I. 89. The polymorph according to clause 88, characterized by an amorphous XRD pattern. 90. The polymorph of any one of clauses 87-88, characterized by an XRD pattern substantially as shown in Figure 47. 91. The polymorph of any one of clauses 87 to 89, characterized by a DSC thermogram substantially as shown in Figure 48. 92. The polymorph of any one of clauses 87 to 90, characterized by a TGA-MS spectrum substantially as shown in Figure 49. 93. The polymorph according to clause 87, wherein said polymorph has Form II. 94. The polymorph of clause 93, characterized by an XRD pattern containing 2θ peaks at 9.9, 17.7, 21.3, and 24.8±0.2 degrees 2θ. 95. The polymorph of any one of clauses 94 to 95, characterized by an XRD pattern substantially as shown in Figure 50. 96. The polymorph of any one of clauses 94 to 96, characterized by a DSC thermogram substantially as shown in Figure 51. 97. The polymorph of any one of clauses 94 to 97, characterized by a TGA-MS spectrum substantially as shown in Figure 52. 98. The polymorph according to clause 87, wherein said polymorph has Form III. 99. The polymorph of clause 98, characterized by an XRD pattern containing 2θ peaks at 9.4, 20.8, 22.7, and 25.6±0.2 degrees 2θ. 100. The polymorph of any one of clauses 98 to 99, characterized by an XRD pattern substantially as shown in Figure 53. 101. Formula (I): [ka] Polymorphism of naphthalene-1,5-disulfonate salt of . 102. The polymorph according to clause 101, wherein said polymorph has Form I. 103. The polymorph of clause 102, characterized by an XRD pattern containing 2θ peaks at 8.3, 12.7, 13.1, 22.4, and 24.1±0.2 degrees 2θ. 104. The polymorph of any one of clauses 102 to 103, characterized by an XRD pattern substantially as shown in Figure 54. 105. A polymorph according to any one of clauses 1 to 104, A pharma- ceutically acceptable carrier; 23. A pharmaceutical composition comprising: 106. A polymorph according to any one of clauses 1 to 104 or a pharmaceutical composition according to clause 117, instructions for using the polymorph according to any one of clauses 1 to 104 or the pharmaceutical composition according to clause 117; Kit including: 107. A method of treating a condition in a subject, comprising: administering to a subject the polymorph of any one of clauses 1 to 104 or the pharmaceutical composition of clause 105. A method comprising: 108. The method of clause 107, wherein the subject is a human. 109. The method of any one of clauses 107 to 108, wherein the condition is cancer or an autoimmune disease.
[0207] Although the foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity of understanding, it will be readily apparent to those skilled in the art in light of the teachings of the invention that certain changes and modifications can be made thereto without departing from the spirit or scope of the appended claims.
[0208] Thus, the above merely illustrates the principles of the present invention. It will be recognized that those skilled in the art can devise various configurations that embody the principles of the present invention and are within the spirit and scope of the present invention, although not expressly described or shown herein. Furthermore, all examples and conditional language recited herein are intended, in principle, to aid the reader in understanding the principles of the present invention and the concepts that the inventors have contributed to the advancement of the art, and should not be interpreted as being limited to such specifically recited examples and conditions. Furthermore, all statements herein reciting the principles, aspects, and embodiments of the present invention and specific examples thereof are intended to encompass both structural and functional equivalents thereof. In addition, such equivalents are intended to include both currently known equivalents and equivalents developed in the future, i.e., any elements developed that perform the same function, regardless of structure. Furthermore, nothing disclosed herein is intended to be made available to the public, regardless of whether such disclosure is expressly recited in the claims.
[0209] The scope of the present invention, therefore, is not intended to be limited to the exemplary embodiments shown and described herein. Rather, the scope and spirit of the present invention is embodied in the appended claims.
Claims
1. Formula (I): 【Chemistry 11】 Polymorphism of the free base of.
2. 2. The polymorph of claim 1, wherein the polymorph has Form I, Form II, or Form III.
3. Formula (I): 【Chemistry 12】 Polymorphism of the tosylate salt of .
4. 4. The polymorph of claim 3, wherein the polymorph has Form I, Form II, Form III, or Form IV.
5. Formula (I): 【Chemistry 13】 Polymorphism of the oxalate salt of.
6. 6. The polymorph of claim 5, wherein the polymorph has Form I, Form II, or Form III.
7. Formula (I): 【Chemistry 14】 Polymorphism of the fumarate salt of .
8. 8. The polymorph of claim 7, wherein the polymorph has Form I, Form II, Form III, Form IV, or Form V.
9. Formula (I): 【Chemistry 15】 Polymorphism of the camsylate salt of .
10. 10. The polymorph of claim 9, wherein the polymorph has Form I, Form II, or Form III.
11. Formula (I): 【Chemistry 16】 Polymorphs of the citrate salt of .
12. 12. The polymorph of claim 11, wherein the polymorph has Form I.
13. Formula (I): 【Chemistry 17】 Polymorphism of the hydrochloride salt of.
14. 14. The polymorph of claim 13, wherein the polymorph has Form I, Form II, or Form III.
15. Formula (I): 【Chemistry 18】 Polymorphism of naphthalene-1,5-disulfonate salt of .
16. A polymorph according to any one of claims 1 to 15; A pharma- ceutically acceptable carrier; 23. A pharmaceutical composition comprising:
17. A polymorph according to any one of claims 1 to 15 or a pharmaceutical composition according to claim 16, Instructions for using the polymorph of any one of claims 1 to 15 or the pharmaceutical composition of claim 16. Kit including:
18. 1. A method of treating a condition in a subject, comprising: Administering to said subject a polymorph of any one of claims 1 to 15 or a pharmaceutical composition of claim 16. A method comprising:
19. 20. The method of claim 18, wherein the subject is a human.
20. 20. The method of any one of claims 18 to 19, wherein the condition is cancer or an autoimmune disease.
